Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Cited by 28 Publications

Cancer Discov, 2019, 9(1):34-45

PubMed: 30297358 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4155-4167

PubMed: 30952643 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.118.224048

PubMed: 30796167 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Biomed Pharmacother, 2019, 112:108699

PubMed: 30970511 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):202

PubMed: 30841886 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.06.097

PubMed: 31277942 ( click the link to review the publication )

Mol Biol Rep, 2019, 10.1007/s11033-019-04892-7

PubMed: 31147860 ( click the link to review the publication )

Leukemia, 2018, 32(4):900-910

PubMed: 29249821 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

J Gastroenterol, 2018, 53(1):71-83

PubMed: 28315004 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):696-706

PubMed: 29453320 ( click the link to review the publication )

Biomed Pharmacother, 2018, 104:204-210

PubMed: 29772441 ( click the link to review the publication )

Br J Haematol, 2017, 10.1111/bjh.14707

PubMed: 28439875 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

Am J Transl Res, 2017, 9(2):454-465

PubMed: 28337274 ( click the link to review the publication )

Alcohol, 2017, 60:95-101

PubMed: 28433417 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

J Immunol, 2015, 10.4049/jimmunol.1403196

PubMed: 25825452 ( click the link to review the publication )

Cell Cycle, 2015, 10.1080/15384101.2015.1044174

PubMed: 25946202 ( click the link to review the publication )

Oncol Lett, 2015, 9(4):1691-1698

PubMed: 25789025 ( click the link to review the publication )
Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):536-46

PubMed: 24704162 ( click the link to review the publication )

Leuk Res, 2014, 38(3):402-10

PubMed: 24484870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methylation ^[1]
(HL-60, KG1a cells)

In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. ^[1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [³H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Eca109	M2nHO2Z2dmO2aX;uJGF{e2G7	M2PmcFAvPcLizszN	NFfaRmEzPCCq	MVT3ZZRmeg>?	MmT1cY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM>	Ml;6NlUyOjNyOEK=
Eca109	MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrHNE42NzJwNT:1JO69VQ>?	NUPJVZNiOjRxNEivO\|IhcA>?	NX;WN2NNf2G2ZYK=	Mkn0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBld3OnLTDhcoQhfGmvZT2g[IVx\W6mZX70JI1idm6nch?=	NUjSSmE2OjVzMkOwPFI>
Eca109	MUXGeY5kfGmxbjDBd5NigQ>?	M4\adVAvPcLizszN	NEG5Wng3NzF{L{K0JIg>	NHzSUXd4[XSnch?=	NFjh[m9qdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg	M3LJS\|I2OTJ\|MEiy
Eca109	NEjuVYtHfW6ldHnvckBCe3OjeR?=	NH70cFgxNjYEoN88US=>	MVeyOEBp	NFTBUGN4[XSnch?=	NHnhZoJqdmirYnn0d{Bk\WyuIHnueoF{cW:w	Mn;zNlUyOjNyOEK=
Eca109	NHTVO\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUSwMlXDqM7:TR?=	M1PRZ\|I1KGh?	M1zOTZdifGW{	NVrucYticW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>?	NIC5XZIzPTF{M{C4Ni=>
Eca109	NYm0U4xITnWwY4Tpc44hSXO\|YYm=	M4rzVVAvPS9zIN88US=>	M36xXVI1KGh?	MlfIe4F1\XJ?	NGrFbHZl\WO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDOSk3PwkJ{IHHu[EBOVVB{	NHH1dWkzPTF{M{C4Ni=>
SW1116	NILle2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\ITFQxNjVxMT:yM\|Uh\|ryP	MUm0PEBp	MmfuSG1UVw>?	M1LxWYVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44>	Mn;INlQ5PzR{OE[=
LOVO	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYiwMlUwOS9{L{Wg{txO	M2\kO\|Q5KGh?	NWO0U2JETE2VTx?=	MXjlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u	MkDjNlQ5PzR{OE[=
SW1116	NHK5bHRHfW6ldHnvckBCe3OjeR?=	NWCyOWplOTBizszN	NY\0PGtMPDhiaB?=	NHPOUopFVVOR	NUeyVXRKcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk	NH3lNpgzPDh5NEK4Oi=>
LOVO	NHL4U4lHfW6ldHnvckBCe3OjeR?=	M1HV[VExKM7:TR?=	M2\LclQ5KGh?	M1zENmROW09?	NHTZN5dqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ?	NFzlXWszPDh5NEK4Oi=>
SW1116	M2HJVGFxd3C2b4Ppd{BCe3OjeR?=	NF\yRnEyOCEQvF2=	M3TXN\|Q5KGh?	NYL6XXlYTE2VTx?=	NWjVdHhj\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{	M{XDZlI1QDd2Mki2
LOVO	M2\qeGFxd3C2b4Ppd{BCe3OjeR?=	MWmxNEDPxE1?	NUOzfmp1PDhiaB?=	MlK0SG1UVw>?	NFL3fYhmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM>	NGXufVQzPDh5NEK4Oi=>
RPMI-8226	M{ftWmFxd3C2b4Ppd{BCe3OjeR?=	MXuxM\|Ih\|ryP	MUG0PE84Oi97NjDo	M{HrV2ROW09?	MYjpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MmXNNlQ5OzNzMEi=
OPM-2	NWGxRmRySXCxcITvd4l{KEG\|c3H5	MUOxM\|Ih\|ryP	M1jIWVczNzl4L{GyNEBp	MYjEUXNQ	NIX2d2hqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NUjHfoZOOjR6M{OxNFg>
JJN3	MULBdI9xfG:\|aYOgRZN{[Xl?	M{H1NFAvPS9zIN88US=>	NUm5Sll{OjRxNEigbC=>	NGL0TYxFVVOR	NYXoeot6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NULiSoVPOjR6M{OxNFg>
NCI-H929	MYPBdI9xfG:\|aYOgRZN{[Xl?	M4TVVlEwOiEQvF2=	NYnxTWU4PzJxOU[vNVIxKGh?	MYPEUXNQ	MUjpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MVmyOFg{OzFyOB?=
RPMI-8226	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTvTJEyNzJizszN	M1rsZ\|I1NzR6L{eyJIg>	M3[3NmROW09?	NV\6WnUz[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm=	MlL1NlQ5OzNzMEi=
OPM-2	NF;OWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjo[VQyNzJizszN	MX[yOE81QC95MjDo	M1P3NmROW09?	M323XIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	MV2yOFg{OzFyOB?=
JJN3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4O1c\|AvPS9zIN88US=>	NFTQVpczPC92OD:3NkBp	NGHEZoFFVVOR	MWPh[oZm[3S\|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>?	MXeyOFg{OzFyOB?=
NCI-H929	MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\oblEwOiEQvF2=	NXTaRWFHOjRxNEivO\|IhcA>?	MVXEUXNQ	M4TWSYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	Mn3VNlQ5OzNzMEi=
HeLa	NV3SZXRIU2mwYYPlJGF{e2G7				M1i3fGtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE>	MmXCNlQ4QDByOUi=
HeLa	NVvuSlkxU2mwYYPlJGF{e2G7				NXKwOYZHU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz	MUOyOFc5ODB7OB?=
HeLa	MVPLbY5ie2ViQYPzZZk>				NVftcWVzU2l;MkGuOkDDuSB\|LkCg{txOKG[xcjDoR25VOQ>?	NGG1SpUzPDd6MEC5PC=>
HeLa	NYD5ZppXU2mwYYPlJGF{e2G7				M1ruTWtqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM>	NGHWd20zPDd6MEC5PC=>
NB4	M1TWT2Z2dmO2aX;uJGF{e2G7	NVy3[FlwOi53L{WvO{42NzFyIN88US=>	MWSyOEBp	MYjEUXNQ	MVnpcoNz\WG\|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh	NYPYcJdIOjR2OES4O\|A>
CD4+ CD25− T	M4XQdmZ2dmO2aX;uJGF{e2G7	M2jrN\|EwPSEQvF2=			M1fTdpJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>?	NInUTJUzPDR5NkO2NC=>
BV-173	NHzFPGhCeG:ydH;zbZMhSXO\|YYm=	MljyNE4zPS9yLkWvNE44PS9zIN88US=>	MnHvOFgwPzJxOU[gbC=>	NYH2RYU5yqCSQmO=	MmG2bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	MoLiNlQ1OjN4MUO=
ML-1	MknVRZBweHSxc3nzJGF{e2G7	Ml7zNE4zPS9yLkWvNE44PS9zIN88US=>	NV;1UpZlPDhxN{KvPVYhcA>?	NFP2c27DqFCEUx?=	MXfpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:\|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK=	NUfjWFZkOjR2MkO2NVM>
HL-60	MX7BdI9xfG:\|aYOgRZN{[Xl?	NEm3bHIxNjJ3L{CuOU8xNjd3L{Gg{txO	NF\sdJM1QC95Mj:5OkBp	NUPmdYdCyqCSQmO=	M{fEOIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=>	NYHDXplyOjR2MkO2NVM>
KG-1a	NEfafmpCeG:ydH;zbZMhSXO\|YYm=	NFjaW2kxNjJ3L{CuOU8xNjd3L{Gg{txO	NVXSXXNLPDhxN{KvPVYhcA>?	NWPYdmp5yqCSQmO=	NF3R[YtqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	NHfqeI4zPDR{M{[xNy=>
BV-173	NYTNN2EzTnWwY4Tpc44hSXO\|YYm=	M37UUFI2OC93MEDuUS=>	MoLxOFghcA>?	Mn\pxsBRSlN?	MmXTbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn	MXSyOFQzOzZzMx?=
CEM	MnXjSpVv[3Srb36gRZN{[Xl?	NGfHUW0zPTBxNUCwcm0>	MorSOFghcA>?	NVrwfVdnyqCSQmO=	M2fKd4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W\|dHHpcoVlKFKRUzDpcoNz\WG\|ZR?=	MY[yOFQzOzZzMx?=
HL-60	NIWxNFFHfW6ldHnvckBCe3OjeR?=	NVzz[VFFOjVyL{WwNI5O	MUO0PEBp	NVjwO205yqCSQmO=	NX63c2R3cW6mdXPld{Bl\WyjeXXkJIFv\CC\|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl	NYnkNlVMOjR2MkO2NVM>
ML-1	M{\wWGZ2dmO2aX;uJGF{e2G7	MVWyOVAwPTBybl2=	M4HnZlQ5KGh?	MWlCpHBDWw>?	NELL[oVqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W=	MmjzNlQ1OjN4MUO=
DLD-1	MkDxSpVv[3Srb36gRZN{[Xl?	NUi3SoduOjVyL{WwNI5O	NYO1NFRXPDhiaB?=	M3\oc:KhWEKV	MUXkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm	NVjXdVdJOjR2MkO2NVM>
HCT-116	NHzrVYhHfW6ldHnvckBCe3OjeR?=	NXjqXXpROjVyL{WwNI5O	MYW0PEBp	NIj6d47DqFCEUx?=	NYXxcVVr\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W\|dHHpcoVlKFKRUzDpcoNz\WG\|ZR?=	NUnUUm9oOjR2MkO2NVM>
U937-A/E-9/14/18	NUfzeZd4SXCxcITvd4l{KEG\|c3H5	MVewMlAyNzBwMT:xM\|ExKM7:TR?=	NGfxSpE1QCCq		Ml\JbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NIjPRoMzPDNyMES1Oi=>
HT29	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXPkZ2RxPzJiaB?=		M13SVmlEPTB;MUSwNOKyOTd7IN88US=>	MVKyOFE4OjB4MR?=
SW48	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFi3VGM4OiCq		MXTJR\|UxRTF3LkNCtVYvOiEQvF2=	NVHk[YVVOjRzN{KwOlE>
HCT116	NFPMSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYi3NkBp		MoT3TWM2OD1zLkhCtVAvPCEQvF2=	NHHBU20zPDF5MkC2NS=>
HepG2	M2fPXmZ2dmO2aX;uJGF{e2G7	Mm\ONE42NzFizszN	NH3iSoczPCCq	NV7CVVdOTE2VTx?=	NHO4NpB2eC2{ZXf1cIF1\WRidHjlJJJmdGG2aY\lJG9EXE5{IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?=	MYOyOFE1Pjh5NB?=
LS174T	NIHwSJRHfW6ldHnvckBCe3OjeR?=	MkjQNE42NzFizszN	NY\SUHFOOjRiaB?=	NVz3ToZKTE2VTx?=	NHjnOW1t\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=>	NH:xe3AzPDF2Nki3OC=>
HepG2	NUXKbVdvSXCxcITvd4l{KEG\|c3H5	MXKxM\|ExNzFyMDFOwG0>	MW[3JIQ>	MWHEUXNQ	M3rFZolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NX;pbnlbOjRzNE[4O\|Q>
LS174T	MoXiRZBweHSxc3nzJGF{e2G7	NUTucWZUOS9zMD:xNFAh\|ryP	NXfxW2hiPyCm	Mn7aSG1UVw>?	NIi5UpFqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NFnWcFQzPDF2Nki3OC=>
QBC-939	M4[2[2Fxd3C2b4Ppd{BCe3OjeR?=	M33kPVEwOTBxMUCwJO69VQ>?	M1HWc\|ch\A>?	MXHEUXNQ	MoLkbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MlrlNlQyPDZ6N{S=
U251	Mk\lRZBweHSxc3nzJGF{e2G7	M3L4bFEwOTBxMUCwJO69VQ>?	NF[4XFA4KGR?	MVXEUXNQ	NYXoVpY5cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M{[xN\|I1OTR4OEe0
HL-60	NGnYUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX6xJO69VQ>?	M3jQNlQ5KGh?		NVPteGFrcW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36=	MUCyOFAxODN{NB?=
MDA‑MB‑453	NYDifJR2TnWwY4Tpc44hSXO\|YYm=	MoHvNE4zNzFizszN	NELZdXM4OiCq		MV;jZZV{\XNicnWt[ZhxemW\|c3nvckBw\iClbHH1[IlvyqBzwrC=	Mk\BNlM5PDR{Mki=
HCC1569	NYi2No1UTnWwY4Tpc44hSXO\|YYm=	MUWwMlIwOSEQvF2=	NITkb4k4OiCq		NIPr[otk[XW\|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA>	NHHUcIQzOzh2NEKyPC=>
BT‑474	MXfGeY5kfGmxbjDBd5NigQ>?	NV;0WnZVOC5{L{Gg{txO	NETQXnU4OiCq		MmH4Z4F2e2W\|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg	NUTEd5I4OjN6NESyNlg>
AGS	NXW0cY1JSXCxcITvd4l{KEG\|c3H5	M3S0V\|UwOTBxMkCvOVAh\|ryP	NGrvfW01QMLiaNMg	MYLEUXNQ	MVTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=>	MmnTNlM2QDJ5OES=
A549	NXu0NY1ESXCxcITvd4l{KEG\|c3H5	NWXqbGJmPS9zMD:yNE82OCEQvF2=	M2LXXFQ5yqCqwrC=	NIHG[m1FVVOR	NE\iXYhqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>?	MnHoNlM2QDJ5OES=
AGS	NWTad\|RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{m3WlUwOTBxMkCvOVAh\|ryP	NIn1R241QMLiaNMg	NVX6b4w3TE2VTx?=	MmXybY5lfWOnczDHNk9OKHCqYYPlJIFzemW\|dNMg	M2jCPFI{PTh{N{i0
Kasumi-1	M4\reGFxd3C2b4Ppd{BCe3OjeR?=	NH\KRnIxNjVizszN	NUHiTYh2PDkEoHlCpC=>		MmW2[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O=	NGDiPZIzOzR7M{O0PC=>
OCI-AML3	NYXvN5JOSXCxcITvd4l{KEG\|c3H5	M4roRVIvPSEQvF2=	NYn5[ZpPPDkEoHlCpC=>		NVrCfZhl\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M>	MYeyN\|Q6OzN2OB?=
MV4-11	MkD0RZBweHSxc3nzJGF{e2G7	M2n1TFIvPSEQvF2=	Mn7LOFjDqGkEoB?=		MnTL[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O=	NIKxWG8zOzR7M{O0PC=>
NK	M1\Nb2N6fG:2b4jpeJkhSXO\|YYm=	NVixXWd2OC5yMj2yNEDPxE1?	NV62PI1mPSCm		NH71dIhl\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2\|aHHw[YQh\G:\|ZfMAl5Jme3CxboPlJIN2en[n	NUTqc\|dDOjN\|MkiwPFg>
NK	MV;BdI9xfG:\|aYOgRZN{[Xl?	M1rSR\|AvODJvMkCg{txO	NInjSFY2KGR?		M{PiWoRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>?	MonuNlM{OjhyOEi=
NK	MVvGeY5kfGmxbjDBd5NigQ>?	NEjUNJYxNjBzLUKwJO69VQ>?	Mn[wOUBl		M2HTV4NifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW\|cH;ud4U>	M{mzRlI{OzJ6MEi4
MOLT4/DNR	NEjTZVVHfW6ldHnvckBCe3OjeR?=	MkXUOUDPxE1?	M4fvZVQh\A>?		NX3lW\|dlemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25?	MYeyN\|A3ODV5MB?=
Jurkat/DOX	NG\WfVhHfW6ldHnvckBCe3OjeR?=	NWHtRY5vPSEQvF2=	MXq0JIQ>		NHjDNW9z\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>?	Mm\jNlMxPjB3N{C=
MOLT4/DNR	Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HaclUh\|ryP	M1K2OFQh\A>?		Mnu3doVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC\|ZX7zbZRqfmm2eR?=	NGHSZlczOzB4MEW3NC=>
Jurkat/DOX	NHTyfYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTJbW42KM7:TR?=	MWS0JIQ>		Moi3doVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC\|ZX7zbZRqfmm2eR?=	M{nHXFI{ODZyNUew
ccRCC	M33nN2Fxd3C2b4Ppd{BCe3OjeR?=	NVHmXG1zOC5yMT2xNO69VQ>?	M3;ONlczKGh?	MWfEUXNQ	MYDoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v	M2fVWFIzQDJ4NE[3
TNBC	Mkf4RZBweHSxc3nzJGF{e2G7	NYfMVnkyOC5yMT2xNO69VQ>?	M3jwUVczKGh?	MV;EUXNQ	MoPQbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>?	MVKyNlgzPjR4Nx?=
A498	NEmwZY1CeG:ydH;zbZMhSXO\|YYm=	MUGwMlAyNTFyzszN	MW[3NkBp	MYjEUXNQ	M4XK[olv\HWlZYOgd5lv\XKpaYP0bYMhemW\|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4>	NIrCUWkzOjh{NkS2Oy=>
KIJ265T	NH3jbGFCeG:ydH;zbZMhSXO\|YYm=	NFHpcWExNjBzLUGw{txO	NVixWmVLPzJiaB?=	NVr5WVF2TE2VTx?=	NYP2PXpncW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>?	MlnDNlI5OjZ2Nke=
MDA-231	M4nUTmFxd3C2b4Ppd{BCe3OjeR?=	M1j0WVAvODFvMUFOwG0>	NISzUYU4OiCq	M4O4fmROW09?	NG\pXXFqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv	NF34XGYzOjh{NkS2Oy=>
BT-20	M3PPb2Fxd3C2b4Ppd{BCe3OjeR?=	MlGyNE4xOS1zMN88US=>	NWnMVHllPzJiaB?=	NWf5R2pLTE2VTx?=	MX\pcoR2[2W\|IIP5coVz\2m\|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu	Mn;DNlI5OjZ2Nke=
U937	M2TEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfEfFl4PS1{MDFOwG0>	MmW2NlQwPDhxN{KgbC=>		MV;pcoR2[2W\|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	MmHLNlI4PjdyMkG=
HL60	NYPhVVRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfTOU0zOCEQvF2=	Mon0NlQwPDhxN{KgbC=>		NVT0fmZxcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	NWf3VXJ4OjJ5NkewNlE>
U937	MnLiRZBweHSxc3nzJGF{e2G7	NX\T[YtuOTVizszN	M3v4elI1NzR6L{eyJIg>		NWHXbVFxcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MorlNlI4PjdyMkG=
HL60	NVfrT3VMSXCxcITvd4l{KEG\|c3H5	NYXpTGtROTVizszN	M4TYVFI1NzR6L{eyJIg>		NV;ldFQ3cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NXjlXZFFOjJ5NkewNlE>
LS411N	NXfxSldxSXCxcITvd4l{KEG\|c3H5	NHf0cnIxNjVizszN	NEjrTIk4OiCq		NWfHbYN3cW6lcnXhd4V{KE[jczDtVm5CKGyndnXs	NUnTPWVrOjJ2NkG2PVU>
MDA-MB-231	MXLBdI9xfG:\|aYOgRZN{[Xl?	MUexNEDPxE1?	NVroSFBtPDhiaB?=		Mn3xdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MXGyNVg5PzZ7Nx?=
MCF-7	NX61fFRESXCxcITvd4l{KEG\|c3H5	Ml;2NVAh\|ryP	MVW0PEBp		MX7y[YR2[2W\|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NG\KWIczOTh6N{[5Oy=>
A375	M1\HZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHEPWw3OC53IN88US=>	Mo\jNU82NzhiZB?=		NV76fYFocW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	M3ezZlIyPzl4NkKy
SKMEL1	M{jKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jwe\|AvPSEQvF2=	M4HUcFEwPS96IHS=		Moi1bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN?	MmiwNlE4QTZ4MkK=
SKMEL3	NVzBZlkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnG3NE42KM7:TR?=	NX:3OWhpOS93L{ig[C=>		MnyzbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN?	MXuyNVc6PjZ{Mh?=
SKMEL28	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TjPVAvPSEQvF2=	MoDrNU82NzhiZB?=		M3[yOolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	NInrRZUzOTd7Nk[yNi=>
MeWo	Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH[wdWQxNjVizszN	M2DEO\|EwPS96IHS=		MYDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	NGDIeI8zOTd7Nk[yNi=>
B16	NI\wNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjRVWgxNjVizszN	MXyxM\|UwQCCm		M2OwfYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	M1zCeVIyPzl4NkKy
Ly 1	M3\adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWPJ[Xd{OjRiaB?=		Ml3iTWM2OD15LkOg{txO	Mm\MNlE4PzJyNEm=
Ly 7	NVfiR3NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV6yOEBp		MVHJR\|UxRTFyLkeg{txO	NX\YO3ZFOjF5N{KwOFk>
Su-DHL6	M{LpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVWyOEBp		M1v4bGlEPTExvK6yNEDPxE1?	M{foNlIyPzd{MES5
Ly 10	Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn;rNlQhcA>?		NUizVVhnUUN3MP-8olIxKM7:TR?=	M3\ST\|IyPzd{MES5
RIVA	M4SxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3O3SVI1KGh?		MlPWTWM2OO,:nkKwJO69VQ>?	MVuyNVc4OjB2OR?=
Su-DHL2	Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{TDZ\|I1KGh?		M3f0XmlEPTExvK6yNEDPxE1?	MYGyNVc4OjB2OR?=
Ly 1	NX:yfFUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnO3OFghcA>?		MYLJR\|UxRTBwM{Sg{txO	M2jpdVIyPzd{MES5
Ly 7	NUGxRYRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEHHT401QCCq		NGj1U5JKSzVyPUCuNFI2KM7:TR?=	Mlm5NlE4PzJyNEm=
Su-DHL6	NIPPfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXy0PEBp		MYXJR\|Ux97zgMkCg{txO	MVWyNVc4OjB2OR?=
Ly 10	NFLTSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGPx[FM1QCCq		M{jSNmlEPTB;MT64JO69VQ>?	MX[yNVc4OjB2OR?=
RIVA	M37tNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1;JelQ5KGh?		MX;JR\|Ux97zgMkCg{txO	NE\5XJkzOTd5MkC0PS=>
Su-DHL2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4rxZVQ5KGh?		NWjzfY9WUUN3ME2xO{41KM7:TR?=	MlLaNlE4PzJyNEm=
Ly 1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1qyW\|czKGh?		NEC3NIlKSzVyPUCuNFEh\|ryP	NVzrOYUyOjF5N{KwOFk>
Ly 7	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{\RcVczKGh?		M{fQSmlEPTB;MD6wNVgh\|ryP	NXv2bmE6OjF5N{KwOFk>
Su-DHL6	MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWTQOopyPzJiaB?=		NGTPPWRKSzVyPUGuOkDPxE1?	MYWyNVc4OjB2OR?=
Ly 10	NV\IWVlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVS3NkBp		M{j6ZmlEPTB;MT6yJO69VQ>?	MoDHNlE4PzJyNEm=
RIVA	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGjMUVk4OiCq		MYjJR\|Ux97zgMkCg{txO	NYDBc5lFOjF5N{KwOFk>
Su-DHL2	NV7hZnA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnH2O\|IhcA>?		NI\m[ZhKSzVyPUGxMlIh\|ryP	MkjBNlE4PzJyNEm=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Survivin / Bcl-2 / p53 / c-Myc / DNMT1; PubMed: 26384351 Oncotarget HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells. p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; PubMed: 25762617 Oncotarget Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations. phospho-p38 / p38 / phospho-NFκB / NFκB; PubMed: 26617834 Int J Clin Exp Pathol Decitabine suppressed the phosphorylation of p38 and NF-κB. p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; PubMed: 26692933 Am J Transl Res DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments. E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; PubMed: 28152502 Oncotarget The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.	26384351 25762617 26617834 26692933 28152502
Immunofluorescence	DNMT1; PubMed: 21303982 Cancer Res Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain). E-cadherin / MMP-9; PubMed: 28152502 Oncotarget Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC.	21303982 28152502
Growth inhibition assay	Cell viability; PubMed: 26384351 Oncotarget Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.	26384351

In vivo

In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand DNA synthesis assay : The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [³H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:^[1]	+ Expand Cell lines: HL-60 and KG1a Concentrations: 0-500 nM Incubation Time: 96 hours Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice. Formulation: Decitabine is dissolved in sterile PBS . Dosages: ≤2.5 mg/kg Administration: Administered via i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	45 mg/mL (197.18 mM)
	Water	10 mg/mL (43.81 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Decitabine SDF

Molecular Weight	228.21
Formula	C₈H₁₂N₄O₄
CAS No.	2353-33-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Deoxycytidine

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04086238	Recruiting	Drug: Decitabine	Healthy	EpiDestiny Inc.	October 9 2019	Phase 1
NCT04113616	Recruiting	Drug: KRT-232\|Drug: Cytarabine\|Drug: Decitabine	Acute Myeloid Leukemia (AML)\|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN)	Kartos Therapeutics Inc.	September 25 2019	Phase 1\|Phase 2
NCT03828084	Completed	Drug: Decitabine	Healthy	EpiDestiny Inc.	April 3 2019	Phase 1
NCT03875287	Recruiting	Drug: Decitabine\|Drug: Cedazuridine	Solid Tumor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Astex Pharmaceuticals	April 17 2019	Phase 1
NCT03593915	Recruiting	Combination Product: Alvocidib Plus Decitabine	Myelodysplastic Syndromes (MDS)	Tolero Pharmaceuticals Inc.	August 29 2018	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is S1200 a racemic mixture or a monomer?
Answer:
S1200 is R form

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine

Cited by 28 Publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Decitabine SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

DNA Methyltransferase Signaling Pathway Map

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine

Cited by 28 Publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Decitabine SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

DNA Methyltransferase Signaling Pathway Map

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)